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16RAPID COMMUNICATION Open AccessBIRC6 (APOLLON) is down-regulated in acute
myeloid leukemia and its knockdown attenuates
neutrophil differentiation
Anna M Schläfli1, Bruce E Torbett2, Martin F Fey1,3 and Mario P Tschan1,3*Abstract
Background: Inhibitors of apoptosis (IAPs) were intensively investigated in the context of cancer where they
promote tumor growth and chemoresistence. Overexpression of the IAP BIRC6 is associated with unfavorable
clinical features and negatively impacts relapse-free survival in childhood acute myeloid leukemia (AML). Currently,
BIRC6 levels in adult primary AML have not been compared to the expression in normal myeloid cells. Thus, we
compared for the first time BIRC6 levels in adult primary AML patient samples to normal myeloid cells and studied
its regulation and function during neutrophil differentiation.
Findings: We found significantly lower BIRC6 levels in particular AML subtypes as compared to granulocytes from
healthy donors. The lowest BIRC6 expression was found in CD34+ progenitor cells. Moreover, BIRC6 expression
significantly increased during neutrophil differentiation of AML cell lines and knocking down BIRC6 in NB4 acute
promyelocytic leukemia (APL) cells significantly impaired neutrophil differentiation, but not cell viability.
Conclusion: Together, we found an association of low BIRC6 levels with an immature myeloid phenotype and
describe a function for BIRC6 in neutrophil differentiation of APL cells.
Keywords: BIRC6, Acute myeloid leukemia, Acute promyelocytic leukemia, ATRA, Neutrophil differentiationIntroduction
BIRC6 (a.k.a. APOLLON, BRUCE) is an exceptionally
large protein of 528 kDa belonging to the family of in-
hibitor of apoptosis (IAP). BIRC6 contains one bacalo-
virus IAP repeat (BIR) domain that shows homology to
the IAP Survivin. Furthermore, BIRC6 is the only IAP
with an ubiquitin-conjugating domain further pointing
to a particular function of this protein in the IAP
family [1]. Several groups reported that BIRC6
executes its function via inhibition of Smac and
Caspase-9 [2, 3]. Moreover, a study in breast cancer
cells revealed that BIRC6 inhibits cell death by p53
destabilization and inactivation of caspase-3 [4]. The
role of p53-dependent BIRC6 effector functions was* Correspondence: mtschan@dkf.unibe.ch
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reproduction in any medium, provided the orconfirmed by investigations of Ren et al. in mice and
human lung cancer cells [5].
Due to their anti-apoptotic function it was hypothe-
sized that overexpression of IAPs might contribute to
tumorigenesis. Survivin, for example, one of the best
studied IAPs is up regulated in most tumors and has
been associated with their chemoresistence [6, 7]. Re-
cently, Houdt et al. [8] observed BIRC6 overexpression
in colon cancer stem cells when compared to more dif-
ferentiated tumor cells. BIRC6 expression protected
colon cancer stem cells from the cytotoxic effects of
oxaliplatin and cisplatin. Furthermore, knocking-down
BIRC6 led to growth inhibition in several cancer cell
lines and xenografted mice and rendered the tumor cells
more sensitive to 5-fluoruracil treatment in vivo and
in vitro [9]. The significance of IAPs in the pathology of
hematological malignancies however remains poorly
understood and controversial data regarding an effect on
prognosis were published. Carter et al. [10] did not find
any prognostic significance for Survivin or XIAP
expression in adult AML samples, whereas BIRC6Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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features and negatively impacts on the 3-year relapse-
free survival in childhood acute myeloid leukemia
(AML) [11]. Similar results were obtained by Ismail
et al. in childhood AML and acute lymphoblastic
leukemia (ALL) [12]. Abe et al. [13] found lower expres-
sion of BIRC6 in bone marrow-derived cells of healthy
donors compared to de novo AML samples.
To our knowledge, BIRC6 levels in primary AML have
never been compared to the respective expression in
normal myeloid cells. Thus, we aimed at comparing
BIRC6 levels in a large cohort (n = 98) of adult AML pa-
tient samples and mature neutrophils from healthy
donors. Since a hallmark of AML is a differentiation
block of hematopoietic precursors at different develop-
mental stages and since this block can be overcome by
treating acute promylocytic leukemia (APL) patients
with all-trans retinoic acid (ATRA) and low dose chemo-
therapy, we also analyzed the role of BIRC6 during neu-
trophil differentiation of AML cells.Materials and methods
Primary patient samples
A cohort of 98 samples from patients with a diagnosis of
primary AML (FAB M0-M4) were enrolled on HOVON/
SAKK (Dutch-Belgian Hematology-Oncology/ Swiss
Group for Clinical Cancer Research Cooperative group)
protocols −04, -04A, -29, and −42 (available at www.
hovon.nl) between 1987 and 2006 [14–18]). All patients
provided written informed consent in accordance with
the Declaration of Helsinki. Patient data are summarized
in the Table 1. In vitro differentiation of CD34+ progeni-
tor cells was done as previously described [19].Cell lines and culture conditions
The acute myeloid leukemia (AML) cell lines HL60, FAB
M2, the ATRA-resistant subline HL60-R, NB4, FAB M3
(acute promyelocytic leukemia; APL), the ATRA-
resistant subline NB4-R2 and HT93 were kept in
RPIMI-1640 culture media (Sigma-Aldrich, Buchs,
Schweiz) containing 10 % foetal bovine serum (FBS). In
order to differentiate the AML cell lines towards granu-
locytes 1 μM all-trans retinoic acid (ATRA) was addedTable 1 AML patient characteristics from the HOVON/SAKK co
Patient characteristics
Cohort Variables Age (y) Sex (female/male) Tota
HOVON/ SAKK Range 17-74 - -
Mean/median/% 43.09/43.00
(mean/median)
59.18/40.82 100
No. of patients 58/40 98
FAB, French-American-British; CK, complex karyotype; NK, normal karyotype.to the cells that were seeded at a density of 0.2x106
cells/ml. Successful neutrophil differentiation was
assessed by CD11b surface and by increased granulocyte
colony-stimulating factor receptor (G-CSFR; CSF3R)
mRNA expression.Quantitative real-time RT-PCR (qPCR) and TaqMan Low
Density Array (LDA)
For RNA extraction the miRCURY RNA Isolation Kit
from Exiqon was used. RT-PCR has been described
elsewhere [19]. Quantitative measurement of BIRC6
and G-CSFR mRNA was performed using the TaqManW
Gene Expression assays Hs00212288_m1 and
Hs00167918_m1, respectively (Applied Biosystems,
Rotkreuz, Switzerland). LDA measurements as well as
data analysis were done as described [20]. HMBS pri-
mers and probes have been described previously [21].
Measurements were carried out on an ABI PRISM
7500 Sequence Detection System (Applied Biosystems,
Rotkreuz, Switzerland).Generation of BIRC6 knock-down cell lines
NB4 cells were transduced with a lentiviral vector
(pLKO.1) expressing a small hairpin (sh)RNA targeting
the BIRC6 mRNA (NM_016252.x-2281s1c1, Sigma-
Aldrich, Buchs, Schweiz). Lentivirus production has
been described previously [19]. As a non-targeting
control we used the SHC002 lentiviral vector. Two
days after transduction, NB4 cells were selected with
1.5ug/ml puromycin (Sigma-Aldrich, Buchs, Schweiz)
for one week.Cell viability assay
For Trypan blue exclusion assay cells were washed with
PBS before diluting 1:10 in 0.4 % Trypan blue solution
(Sigma-Aldrich, Buchs, Switzerland). For AnnexinV
staining 1x105 cells were washed in 500 μl binding buf-
fer (PBS with 0.33 g/L Ca2+) and resuspended in a final
volume of 100 μl. 5 μl AnnexinV-PE were added
(Immunotools, Germany) and the samples were incu-
bated for 15 minutes at room temperature, before FACS
analysis.hort
FAB classification Cytogenetics
l M0 M1 M2 M3 M4 t(8;21) inv (16) t(15;17) CK NK
4.08 16.33 32.65 19.39 27.55 20.41 17.35 20.41 23.47 18.37
4 16 32 19 27 20 17 20 23 18
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Differences between two groups were assessed using the
non-parametric Mann–Whitney-U test. P-values <0.05
were considered to be statistically significant.
Results
Repression of BIRC6 mRNA in AML patients with
particular chromosomal aberrations
To study the BIRC6 expression patterns in normal ver-
sus leukemic myeloid cells, we measured BIRC6 levels in
a large cohort of 98 primary AML patients (FAB M0-
M4), in 24 granulocyte preparations from healthy donors
and in 3 CD34+ progenitor cell samples. We were able
to detect BIRC6 in 95/98 AML patient, in 14/24 granu-
locytes and in 3/3 CD34+ progenitor cell samples. Sur-
prisingly, we found significantly lower BIRC6 levels in
AML patients with the translocations t(8;21) and t
(15;17) as well as in AML patients with a complex
karyotype, whereas no significant differences in BIRC6
expression was found in AML patients with inv(16) or
normal karyotype as compared to its expression levels in
granulocytes from healthy donors (Figure 1). We found
the lowest BIRC6 mRNA levels in in CD34+ progenitor
cells (Figure 1). Together, our data suggest an associ-
ation of low BIRC6 expression with an immature mye-
loid phenotype.
Significant BIRC6 inductions during ATRA-induced
neutrophil differentiation
In order to assess a possible role of BIRC6 in neutro-
phil differentiation of AML cells, we took advantage of
several AML cells line models for neutrophilBIRC6
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Figure 1 BIRC6 mRNA expression is significantly lower in
particular AML subtypes as compared to granulocytes. Relative
expression levels of BIRC6 mRNA were determined by qPCR analysis.
Raw Ct values were normalized to HMBS and ABL1 (−ΔCt) and
represent log2 expression levels. BIRC6 expression in AML subtypes
FAB M0-M4 and the following molecular lesions: (inv(16),
t(8;21), t(15;17), Comp. = Complex Karyotype, Norm. = Normal
Karyotype). Relative BIRC6 expression levels were compared to the
relative expression in granulocytes from healthy donors (Gran.) and
CD34+ progenitor cells. Mann–Whitney U test *p < 0.05, **p < 0.01,
ns not significant.differentiation. First, we differentiated NB4 APL cells
with ATRA towards neutrophils. In accordance with
the low BIRC6 expression in undifferentiated AML
patients compared to mature neutrophils, BIRC6
mRNA levels were up-regulated 1.8- and 3.6-fold at day
4 and 6 of ATRA treatment, respectively (Figure 2A).
In order to exclude a direct effect of ATRA on BIRC6
expression, we also treated ATRA-resistant NB4-R2
APL cells with ATRA. BIRC6 transcripts were only
marginally up-regulated in these cells further support-
ing a particular role of BIRC6 in neutrophil differenti-
ation (Figure 2B). Neutrophil differentiation of NB4 and
NB4-R2 cells was assessed by CD11b surface expression
(Figure 2C). A similar induction of BIRC6 mRNA ex-
pression upon neutrophil differentiation was seen in
HT93 APL cells (data not shown). In a further experi-
ment, we determined BIRC6 expression in HL60 and
ATRA-resistant HL60-R AML cells during neutrophil
differentiation. We observed a significant 1.6- and 2.8-
fold increase of BIRC6 transcript expression at day 4
and 6, respectively. No significant change in BIRC6 ex-
pression was seen in HL60-R cells upon 4 days of
ATRA treatment, whereas at day 6 a minor but signifi-
cant increase was seen (Figure 2D and E). Neutrophil
differentiation in HL60 cells was confirmed by CD11b
FACS analysis (Figure 2F). ). Consistent with our data
showing increased BIRC6 expression upon neutrophil
differentiation of NB4 and HL60 AML cells, we
observed a 3.3- and 2.8-fold increase in BIRC6 mRNA
expression at day 3 and 6 upon in vitro granulocytic
differentiation of CD34+ progenitor cells, respectively
(data not shown).
Overall, our findings clearly show an association of
increased BIRC6 expression with neutrophil develop-
ment of AML and CD34+ progenitor cells.
Knocking down BIRC6 attenuates neutrophil
differentiation but not cell death and proliferation of
APL cells
To test if specific BIRC6 depletion inhibits neutrophil
differentiation of APL cells, we generated NB4 BIRC6
knockdown cells. BIRC6 knockdown efficiency was con-
firmed in control and ATRA-treated shBIRC6 expressing
NB4 cells (Figure 3A). Neutrophil development as deter-
mined by G-CSFR mRNA as well as CD11b surface ex-
pression was on average 50 % reduced compared to the
non-targeting control transduced NB4 cells at day 4 of
ATRA treatment (Figure 3B-C).
Since BIRC6 is involved in the inhibition of apoptosis,
we were asking if the observed lack of neutrophil differ-
entiation in NB4 BIRC6 knockdown cells is due to
increased cell death in these cells. For this purpose we
assessed cell death by Trypan blue exclusion and
Annexin V flow cyotometry at day 4 and 6 of ATRA
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Figure 2 Significant induction of BIRC6 mRNA levels upon neutrophil differentiation of AML cells. (A) BIRC6 qPCR analysis of NB4 APL cells
treated with 1 μM ATRA for 4 and 6 days. Raw Ct values were normalized to HMBS and to the untreated control of day 4. Results from four
independent experiments in duplicates are shown. (B) BIRC6 qPCR analysis of ATRA-resistant NB4-R2 APL cells treated as in A. (C) CD11b surface
expression of NB4 and NB4-R APL cells upon six days of ATRA-induced neutrophil differentiation. CD11b was measured by FACS analysis. (D)
Neutrophil differentiation of HL60 AML cells with 1 μM ATRA for 4 and 6 days, respectively. BIRC6 mRNA expression was assessed by qPCR as in
A. (E) BIRC6 qPCR analysis of ATRA-resistant HL60-R cells treated as in A. (F) The differentiation levels of HL60 and HL60-R were assessed by CD11b
surface expression upon 6 days of ATRA-induced neutrophil differentiation. Mann–Whitney U test *p < 0.05, **p < 0.01, ***p < 0.001, ns not
significant.
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http://www.ehoonline.org/content/1/1/25treatment. We did not find any significant differences
in cell viability between NB4 control and BIRC6
knockdown cells during ATRA-induced neutrophil
differentiation (Figure 3D and E). Furthermore, control
transduced as well as BIRC6 knockdown NB4 cells
showed no significant differences in total cell counts at
day 4 and 6 of ATRA treatment (Figure 3F).
In summary, we showed that inhibiting BIRC6 signifi-
cantly affects neutrophil differentiation of APL cells, but
not cell viability.
Discussion
In this report we publish for the first time that AML pa-
tient samples with the t(8;21), the t(15;17) or a complex
karyotype express BIRC6 significantly lower than normal
human granulocytes. Subtype-specific BIRC6 expression
in AML is supported by earlier findings published byIsmail et al. [12]. Low expression of the anti-apoptotic
IAP BIRC6 in AML may seem controversial given the
often high expression of IAPs in cancer. Our findings of
high BIRC6 expression in granulocytes versus AML may
reflect the cellular differentiation status of these cells ra-
ther than a cancer-associated deregulation. This hypoth-
esis is confirmed by our observation that BIRC6 mRNA
levels are clearly reduced in CD34+ myeloid precursor
cells and increase during granulocyte differentiation.
These data are in line with previous findings showing
that BIRC6 is down-regulated in bone marrow-derived
cells if compared to de novo AML samples [13]. Fur-
thermore, the expression of the BIRC6 related XIAP is
induced upon monocyte differentiation and contributes
to monocyte cell survival. In the same study, XIAP
levels declined during neutrophil differentiation sup-
porting the cell type specific regulation of IAPs in
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Figure 3 Knocking-down BIRC6 attenuates neutrophil differentiation of APL cells. (A) NB4 BIRC6 knock-down cells (shBIRC6) were generated
by lentiviral transduction of shRNAs targeting the BIRC6 mRNA. BIRC6 knockdown efficiency compared to control transduced (SHC002) NB4 cells
was determined by qPCR analysis. Values are shown as n-fold regulation compared to control transduced cells. (B,C) NB4 shBIRC6 and SHC002
were treated with 1 μM ATRA for 4 and 6 days, respectively. Neutrophil differentiation was determined by G-CSFR mRNA and CD11b surface
expression. The raw Ct values of G-CSFR were normalized to HMBS and to the Ct values of the respective control transduced cells under ATRA
treatment. CD11b expression is shown as mean fluorescence intensity (MFI). (D,E) Cell death in BIRC6 knock-down cells at day 4 and 6 of ATRA
treatment was assessed by AnnexinV staining and Trypanblue exclusion assays. Data are given as percentage or total number of death cells,
respectively. (F) Total cell counts were determined using a hemocytometer. There was no difference in total cell number at day 4 or 6 of ATRA
treatment between shBIRC6 or control NB4 cells. Mann–Whitney U test **p < 0.01, ***p < 0.001, ns not significant.
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cific expression of XIAP, a correlation of XIAP levels
with monocytic markers in AML was found [23]. In
contrast to these finding in adult AML, in childhood de
novo acute myeloid leukemia the levels of XIAP corre-
lated with an immature FAB-subtype [24]. This may
suggest different XIAP functions in distinct leukemic
entities.
In conclusion, we were able to link increased BIRC6
mRNA expression with neutrophil differentiation and
inhibiting BIRC6 resulted in attenuated neutrophil dif-
ferentiation but did not alter cell survival. In summary,
we established a new role for BIRC6 in neutrophil differ-
entiation of AML cells.
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